Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Print
Download
Ovarian Cancer
Phase 1 Trial of Ribociclib (LEE-011) with Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer
ARIEL4 Results of Rucaparib versus Chemotherapy in Patients with Advanced, Relapsed Ovarian Cancer and a Deleterious BRCA Mutation
Read More
Ovarian Cancer
Progression-Free Survival Benefit from Maintenance Olaparib in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA and Other Homologous Recombination Repair Gene Mutation Status (ORZORA Trial)
Read More
Ovarian Cancer
Olaparib Treatment in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Secondary Safety Results from the Phase 2 LIGHT Study
Read More
Ovarian Cancer
5-Year Follow-Up of the SOLO1/GOG 3004 Trial of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation
Read More
Ovarian Cancer
Subgroup Analysis of the ARIEL4 Study of the Effect of Platinum Sensitivity on Efficacy of Rucaparib versus Chemotherapy for BRCA-Mutated, Advanced, Relapsed Ovarian Carcinoma
Read More
Ovarian Cancer
Analysis of the Phase 3 PAOLA-1/ENGOT-ov25 Trial by Disease Stage in Patients with Homologous Recombination Deficiency–Positive Newly Diagnosed Advanced Ovarian Cancer Receiving Bevacizumab with Olaparib/Placebo Maintenance
Read More
Ovarian Cancer
EFFORT Study of Adavosertib with or without Olaparib in Women with PARP-Resistant Ovarian Cancer
Read More
Ovarian Cancer
Final Overall Survival Results from the LIGHT Study of Olaparib Treatment in Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status
Read More
Ovarian Cancer
Phase 3b OPINION Primary Analysis of Olaparib Maintenance Monotherapy for Nongermline BRCA1/2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
Read More
1
2
3
Page 3 of 3
Results 21 - 30 of 30